CLINICAL_TRIALS
ClinicalTrials.gov record update
A Randomized Phase II Study of ALIMTA® (Pemetrexed) and GEMZAR® (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT00407550
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:37:18.722221+00:00
- Published At
- 2012-06-13T00:00:00+00:00
- Record Updated At
- 2019-05-02
- Results Posted At
- 2012-06-13
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Lung Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-05-02"- protocolSection.identificationModule.nctId
"NCT00407550"- protocolSection.identificationModule.officialTitle
"A Randomized Phase II Study of ALIMTA\u00ae (Pemetrexed) and GEMZAR\u00ae (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2012-06-13"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.